Skip to main content

Climb Bio, Inc 8-K, filed Oct 23, 2026

Climb Bio, Inc. (CLYM)

8-K 2026-10-23 For: 2026-10-23
View Original
Added on October 23, 2026

About this 8-K

Climb Bio, Inc filed this 8-K on October 23, 2026.

Climb Bio and Mabworks reported additional Phase 1 CLYM116/MIL116 data in healthy volunteers. CLYM116 showed an estimated half-life of approximately 33 days, and a single SC injection of 480 mg or higher produced free APRIL suppression of 90% or more through the full 12-week dosing interval. An 800 mg dose produced approximately 70% reduction in Gd-IgA1 at 12 weeks. AI summary

Items reported

  • Item 7.01: Regulation FD disclosure
  • Item 8.01: Other events
  • Item 9.01: Financial statements and exhibits